Erivedge and Methotrexate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Erivedge and Methotrexate. Common interactions include dyspnoea among females and muscle spasms among males.

The phase IV clinical study analyzes what interactions people who take Erivedge and Methotrexate have. It is created by eHealthMe based on reports of 26 people who take Erivedge and Methotrexate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On May, 22, 2022

26 people who take Erivedge and Methotrexate together, and have interactions are studied.


What is Erivedge?

Erivedge has active ingredients of vismodegib. eHealthMe is studying from 5,794 Erivedge users for its effectiveness, alternative drugs and more.

What is Methotrexate?

Methotrexate has active ingredients of methotrexate sodium. It is often used in rheumatoid arthritis. eHealthMe is studying from 475,302 Methotrexate users for its effectiveness, alternative drugs and more.

Number of Erivedge and Methotrexate reports submitted per year:

Erivedge and Methotrexate drug interactions.

Common Erivedge and Methotrexate drug interactions by gender *:

female:

  1. Dyspnoea
  2. Wheezing
  3. Renal impairment
  4. Alopecia
  5. Cerebrovascular accident
  6. Dumping syndrome
  7. Haemoglobin increased
  8. Hypertension
  9. Panic attack
  10. Pneumonia

male:

  1. Muscle spasms
  2. Nausea
  3. Decreased appetite
  4. Mass
  5. Squamous cell carcinoma
  6. Asthenia
  7. Hypoaesthesia
  8. Blood bilirubin decreased
  9. Death
  10. Diabetes mellitus

Common Erivedge and Methotrexate drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Muscle spasms
  2. Nausea
  3. Death
  4. Decreased appetite
  5. Mass
  6. Squamous cell carcinoma
  7. Hypoaesthesia
  8. Diabetes mellitus
  9. Drug hypersensitivity
  10. Epistaxis

Common conditions people have *:

  1. Basal Cell Carcinoma (a skin cancer, it rarely metastasizes or kills): 24 people, 92.31%
  2. High Blood Pressure: 4 people, 15.38%
  3. Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 11.54%

* Approximation only. Some reports may have incomplete information.

Do you take Erivedge and Methotrexate?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Erivedge and Methotrexate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Erivedge interactions:

Browse all interactions between Erivedge and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Methotrexate interactions:

Browse all interactions between Methotrexate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on vismodegib and methotrexate sodium (the active ingredients of Erivedge and Methotrexate, respectively), and Erivedge and Methotrexate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: